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AbstrACt
Objectives To investigate the characteristics and 
healthcare utilisation of high-cost patients and to compare 
high-cost patients across payers and countries.
Design Systematic review.
Data sources PubMed and Embase databases were 
searched until 30 October 2017.
Eligibility criteria and outcomes Our final search 
was built on three themes: ‘high-cost’, ‘patients’, and 
‘cost’ and ‘cost analysis’. We included articles that 
reported characteristics and utilisation of the top-X% 
(eg, top-5% and top-10%) patients of costs of a given 
population. Analyses were limited to studies that covered 
a broad range of services, across the continuum of care. 
Andersen’s behavioural model was used to categorise 
characteristics and determinants into predisposing, 
enabling and need characteristics.
results The studies pointed to a high prevalence of 
multiple (chronic) conditions to explain high-cost patients’ 
utilisation. Besides, we found a high prevalence of 
mental illness across all studies and a prevalence higher 
than 30% in US Medicaid and total population studies. 
Furthermore, we found that high costs were associated 
with increasing age but that still more than halve of high-
cost patients were younger than 65 years. High costs were 
associated with higher incomes in the USA but with lower 
incomes elsewhere. Preventable spending was estimated 
at maximally 10% of spending. The top-10%, top-5% 
and top-1% high-cost patients accounted for respectively 
68%, 55% and 24% of costs within a given year. Spending 
persistency varied between 24% and 48%. Finally, we 
found that no more than 30% of high-cost patients are in 
their last year of life.
Conclusions High-cost patients make up the sickest and 
most complex populations, and their high utilisation is 
primarily explained by high levels of chronic and mental 
illness. High-cost patients are diverse populations and vary 
across payer types and countries. Tailored interventions 
are needed to meet the needs of high-cost patients and to 
avoid waste of scarce resources.
bACkgrOunD 
It is widely known that healthcare costs 
are concentrated among a small group of 
‘high-cost’ patients.1 Although they receive 
substantial care from multiple sources, crit-
ical healthcare needs are unmet and many 
receive unnecessary and ineffective care.2–5 
This suggests that high-cost patients are a 
logical group to seek for quality improvement 
and cost reduction.
Especially in the USA, many providers 
or insurance plans have pursued this logic 
and developed programmes for ‘high-need, 
high-cost patients’. So far, such programmes, 
including, for example, care coordination 
and disease management, have had favour-
able results in quality of care and health 
outcomes and mixed results in their ability to 
reduce hospital use and costs.6 Research has 
shown that the effectiveness and efficiency 
of the programmes increase when interven-
tions are targeted to the patients that most 
likely benefit.2 7 8 Little is known, however, 
about variations in clinical characteristics and 
care-utilisation patterns across payer-defined 
groups or countries.9 Such insight in the 
health requirements of high-cost patients is 
prerequisite for designing effective policy or 
programme responses.
We conducted this systematic review to 
synthesise the literature on high-cost patients’ 
characteristics and healthcare utilisation. 
Andersen’s behavioural model (see Methods 
section) was used to organise the findings. 
Our analysis was aimed at identifying drivers 
of costs that matter across payer types and 
countries. We aimed to inform the develop-
ment of new interventions and policy, as well 
as future research in high-cost patients. 
strengths and limitations of this study
 ► Based on an extensive literature search, this review 
included 55 studies of high-cost patients’ character-
istics and healthcare utilisation.
 ► Andersen’s behavioural model was used to cate-
gorise the characteristics of high-cost patients into 
predisposing, enabling and need characteristics.
 ► Grey literature was not included in our systematic 
review. However, we identified 55 studies and com-
pared high-cost patients’ characteristics and health-
care utilisation across payers and countries.
 ► We did not assess the quality of the studies because 
of the methodological diversity of the studies.
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Our methodology was based on established guidance for 
conducting systematic reviews.10 11 Our main research 
questions was ‘Who are the most expensive patients, 
what health care services do they use, what drives these 
high costs, and what drivers matter across payers and 
countries?’.
study selection
A preliminary search in PubMed was conducted to iden-
tify key articles and keywords. On the basis of these find-
ings, we developed a search strategy covering the most 
important terms. We then reshaped the search strategy 
by consulting an information specialist of our university. 
The final search was built on three themes: ‘high-cost’, 
‘patients’, and ‘cost’ and ‘cost analysis’. The sensitivity 
of the search was verified with the key articles we found 
earlier. We searched PubMed and Embase on 30 October 
2017. Full details of our search strategy are attached in 
online supplementary appendix 1.
Inclusion and exclusion criteria
Articles were reviewed by author A using title and 
abstract to identify potentially eligible studies. Author 
B verified a random sample of articles to guarantee 
specificity and sensitivity of the selection process. 
Only studies from high-income countries—as defined 
by the World Bank12—and studies published in 2000 
and later were included. Studies not written in English 
and conference abstracts were excluded. In the second 
step, titles and abstracts were reviewed by author A to 
assess whether articles fit within our definition of high-
cost patients: the article reported characteristics and 
utilisation of the top-X% (eg, top-5% and top-10%) 
patients of costs of a given population. Author B veri-
fied a random sample of articles at this selection step. 
In the third step, full-text articles were retrieved and 
independently screened by author A and author B 
for our inclusion criteria. At this step, we aimed for 
studies covering a broad range of services across the 
continuum of care at health system level and excluded 
all studies with a narrow scope of costs (eg, hospital 
costs and pharmaceutical costs) and all studies with 
a narrow population base (primarily disease oriented 
studies, or studies in children). At each step of this 
selection process, (in-)consistencies were discussed 
until consensus was reached. On basis of the discus-
sions, the criteria were refined, and the prior selec-
tion process was repeated.
Data extraction
A data extraction form was developed by the research 
team to ensure the approach was consistent with the 
research question. Author A extracted all data. To 
guarantee specificity and sensitivity of data extraction, 
author B and author C both independently extracted 
the data of five random articles. A meeting was held 
to discuss (in-)consistencies in extraction results. On 
basis of this discussion, the data extraction form was 
refined, and the prior data extraction was repeated. 
Per article, the following key elements were extracted: 
author, year, country, definition of high-cost patients, 
inclusion and exclusion criteria of the study popula-
tion, cost data used to determine total costs, charac-
teristics of the high-cost patients such as diagnoses, 
age, gender, ethnicity, determinants for high costs 
including associated supply side factors (concerning 
the supply of health services), subpopulations and 
healthcare use and costs (per subpopulation). We also 
made a narrative summary of the findings per article 
(provided in online supplementary appendix 2). To 
identify the most important medical characteristics, 
only those diseases with a high prevalence (≥10%) 
among high-cost patient populations or medical char-
acteristics overrepresented in high-cost populations 
were extracted. Medical characteristics (prevalent 
diseases) were categorised and presented at the level 
of International Statistical Classification of Diseases, 
10th Revision (ICD-10) chapters.
Data synthesis
Andersen’s behavioural model was used to categorise 
characteristics and determinants for high costs into 
predisposing, enabling and need characteristics. Ander-
sen’s model assumes that healthcare use is a function 
of (1) characteristics that predispose people to use or not 
to use services, although such characteristics are not 
directly responsible for use (eg, age, gender, education, 
ethnicity and beliefs); (2) enabling characteristics that facil-
itate or impede use of services (income/wealth/insurance 
as ability to pay for services, organisation of service provi-
sion and health policy); and (3) needs or conditions that 
laypeople or healthcare providers recognise as requiring 
medical treatment. The model also distinguishes between 
individual and contextual (measured at aggregate level, 
such as measures of community characteristics) deter-
minants of service use. Andersen hypothesised that the 
variables would have differential ability to explain care 
use, depending on the type of service. For example, 
dental care (and other discretionary services) would be 
explained by predisposing and enabling characteristics, 
whereas hospital care would primarily be explained by 
needs and demographic characteristics.13 14
We presented all data according to five general cate-
gories, including study characteristics, predisposing char-
acteristics, enabling characteristics, need characteristics, 
and expenditure categories and healthcare utilisation. 
We presented summary tables of results, extracted central 
themes and topics from the studies and summarised them 
narratively. All studies were analysed according to payer 
and country to identify the most important drivers across 
settings.
Patient and public involvement
Patients and or public were not involved in the conduct 
of this study.
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general information
Our search strategy resulted in 7905 articles. After first 
broad eligibility assessment, 767 articles remained. After 
screening of titles and abstracts, 190 articles remained 
for full-text screening, from which 55 were ultimately 
included (figure 1).
A description of the studies is given in table 1. The 
majority of the studies were conducted in the USA (n=42). 
The remaining studies were conducted in Canada (n=9), 
Germany (n=1), Denmark (n=1), the Netherlands (n=1) 
and Taiwan (n=1). All were retrospective cohort studies, 
and descriptive and logistic regression analysis were the 
main analytic approaches used. The study period ranged 
from 6 months to 30 years. The most frequent observa-
tion period was 1 year.
A range of definitions for high-cost patients were 
used, and some studies used more than one definition 
to distinguish between age groups, between high-cost 
and very high-cost patients or to study persistently high-
cost patients (>1 year high costs). In general, patients 
belonging to the top-1%, top-5%, top-10% or top-20% of 
spending were considered high-cost patients.
Figure 1 Flow diagram of article selection.
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The study population differed between the studies. We 
categorised eighteen studies as ‘total population’ studies, 
including studies in universal insurance schemes (of all 
ages; nine Canadian studies, one Dutch, one German and 
one Danish study), studies that combined data of different 
payers or survey studies. Respectively 9, 7 and 14 studies 
were among US Medicare, US Medicaid or US commer-
cial populations. The remaining studies compared high-
cost patients in multiple US payers or were among US 
dual eligibles (eligible for both Medicare and Medicaid), 
US Veterans Affairs (VA) beneficiaries or among elderly 
in the Taiwanese insurance system. Some studies used 
additional criteria to determine the population. Age, 
healthcare use or insurance were most frequently used as 
secondary condition to determine the population.
In 50 studies, total costs per patient were based on the 
insurance plan or public programme. In the remaining 
studies, total costs were based on a survey or identified 
from a variety of sources.
Predisposing characteristics
Table 2 presents predisposing, enabling and need char-
acteristics associated with high-cost patients. Age was 
related to high-cost patients in several ways. First, high-
cost patients were generally older, and higher age was 
associated with high costs. This held for each payer type. 
Second, persistently high-cost patients were generally 
older than episodic high-cost patients, and higher ages 
were associated with persistently high costs. Third, the 
magnitude of cost concentration and the threshold for 
high costs differed between age groups.15 As younger 
groups are generally healthier, costs are concentrated 
among fewer individuals. Fourth, clinical diagnoses and 
utilisation patterns varied across age groups,15–17 and 
some subgroups were related to particular ages, including 
mental health high-cost patients among younger ages.18 
Finally, although age was related to high costs, total popu-
lation studies showed that approximately half of the high-
cost populations were younger than 65 years.17 19
Studies showed inconsistent results for gender. Respec-
tively 9 and 16 studies noted males and females were over-
represented in high-cost patients. Besides, gender was 
associated with different segments of the high-cost popu-
lation, including males in top-1% or persistently extreme-
cost patients, and females in top-2%–5% or persistently 
high-cost patients,17 20 or males in mental health high-cost 
patients.18
Eleven studies reported the association between 
ethnicity and high costs. In two Canadian total popula-
tion studies and three US Medicaid studies, whites were 
over-represented among high-cost populations, whereas 
in four US Medicare studies blacks were over-represented.
Socioeconomic status is regarded as both a predis-
posing characteristic and an enabling characteristic 
in Andersen’s model, and we found evidence for both 
relationships. One Canadian study found that high 
costs were most strongly associated with food insecurity, 
lower personal income, non-homeownership and living A
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Table 2 Predisposing, enabling and need factors for high-cost patients
Variables Number of studies
Predisposing factors
Age 3217 20–22 24–31 34–36 57 59–62 65 67–72 76 77 79 81 82
  Gender=male 917 18 20 22 26 27 36 78 83
  Gender=female 1617 19 20 24 25 29–31 59–61 65 67 72 75 81
  Ethnicity=black/African–American 426–28 82
  Ethnicity=white 521 24 61 67 83
  Ethnicity=less likely black or Hispanic 331 67 83
  Ethnicity=less likely immigrant 121
  Ethnicity=less likely whites 2 75 76
  Region 426 67 72 74
  Urban residence 619 26 28 34 36 75
  Rural residence 2 22 72
  Living institutionalised 320 27 66
  Employment status: early retiree 172
  Job satisfaction 160
  Marital status: divorced/widow/separated/living 
alone
2 34 65
  Dependents less likely to incur high costs 170
  Receive care in many census divisions 127
  Harmful habits 324 60 79
  Union membership 172
  Education: less than a high-school degree 
(neighbourhod level)
176
Enabling factors
  Health insurance
   Medicare: more likely dual eligible 626–28 39 75 82
   Medicaid: specific eligibility status 436 61 67 83
   Commercial: increased insurance 2 59 72
   Total population: insurance status had no effect 131
   Type of insurance 170
  Income
   Positive relation with high costs 331 65 72
   Negative relation 518 21 22 71 81
   No relation 324 27 34
  Organisational enabling factors
  Primary care physician supply 126
  Specialist physician supply 126
  Hospital bed supply 126
  Medical specialist as usual source of care 127
  Proportion of physicians who are medical 
specialists
2 28 27
  Inadequate time during office visits 127
  Proportion of providers operating for profit 2 28 27
  Teaching hospitals 128
  Low nurse-to-staffing ratios 128
  Low supply of long-term care beds 128
Continued
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in highly deprived or low ethnic concentration neigh-
bourhoods.21 Other studies found that social deprivation 
seemed to increase risk for high costs more than material 
deprivation.22
Ganguli et al studied health beliefs among high-cost US 
Medicare patients: socioeconomic status, social network, 
patient activation and relationships with and trust in the 
clinician and the health system all increased or decreased 
costs, depending on the context. Trust was particularly 
important and modified the interaction between patient 
activation and costs: when patients trusted their physi-
cians, patient activation was associated with lower costs. 
When trust was lacking, patient activation was associated 
with higher costs.23
Health behaviours, including underweight, obesity, 
physical inactivity and former smoking were significantly 
related to high costs.24 25
Enabling characteristics
The studies’ abilities to assess the effect of insurance were 
limited because most study populations were determined 
by insurance. Nevertheless, the studies indicated that 
increased insurance may have indicated specific or addi-
tional care needs. For example, six US Medicare studies 
Variables Number of studies
  Regular medical doctor or hospital 179
  Regular medical doctor (negative relation) 124
Need factors
  A00–B99 Certain infectious and parasitic 
diseases
915 17 20 21 25 62 65 72 83
  C00–D48 Neoplasms 2115 17 21 22 25 26 28 29 34 35 37 38 72 73 75–78 81 82 85
  D50–D89 Diseases of the blood and blood-
forming organs and certain disorders involving 
the immune mechanism
416 20 35 81
  E00–E90 Endocrine, nutritional and metabolic 
diseases
3216 17 20–22 25 26 28–30 32–34 36 37 58–60 62 66–68 70 73 75 77–79 81 82 84 85
  F00–F99 Mental and behavioural disorders 349 15–18 20–22 24 26 28 29 33 36 38 39 60–63 66 67 70–73 75 77–79 81–83 85
  G00–G99 Diseases of the nervous system 1017 20 25 32 37 38 62 75 81 83
  H00–H59 Diseases of the eye and adnexa 517 21 36 38 81
  I00–I99 Diseases of the circulatory system 369 15–18 20–22 26 28 29 32–35 37–39 58–60 62 66 68 70 72 73 75–79 81 82 84 85
  J00–J99 Diseases of the respiratory system 309 15–17 20–22 26 28–30 32 34 36–38 58 59 62 65 67 70 73 75 77–79 81 82 84
  K00–K93 Diseases of the digestive system 917 18 20 21 38 72 73 81 83
  L00–L99 Diseases of the skin and subcutaneous 
tissue
517 20 21 36 81
  M00–M99 Diseases of the musculoskeletal 
system and connective tissue
159 17 20 21 28 35 60 62 72 73 75 77 78 81 85
  N00–N99 Diseases of the genitourinary system 229 16 17 20–22 26 28–30 32 34 35 37 38 70 72 73 75 78 81 82
  O00–O99 Pregnancy, childbirth and the 
puerperium
515 36 39 63 81
  Q00–Q99 Congenital malformations, 
deformations and chromosomal abnormalities
132
  R00–R99 Symptoms, signs and abnormal clinical 
and laboratory findings, not elsewhere classified
617 21 36 60 78 81
  S00–T98 Injury, poisoning and certain other 
consequences of external causes
915 17 21 36 38 72 75 76 78
  Z00–Z99 Factors influencing health status and 
contact with health services
317 21 38
  Chronic illness 2215 17 20 24 28–30 32–34 36 39 57 59 69 70 73 75 77 81 82 85
  Multimorbidity/burden of comorbid illness 319 17 19 20 24–27 29 35 36 39 57 58 60 63 64 68–70 72–75 77 81–85
  Decedents/survival 1415–17 19 20 27 31–33 36 57 75 81 82
  Activities daily living 731 34 59 65 66 69 74
  Health status 924 31 33 34 37 59 65 69 74
Table 2 Continued 
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reported that high-cost patients were more likely dually 
eligible, and four US Medicaid studies reported that 
certain eligibility statuses were associated with high costs. 
In addition, increased insurance was associated with high 
costs because it lowers costs. Two US commercial studies 
mentioned that high-cost patients were more likely to 
have a health maintenance organisation plan, a preferred 
provider organisation plan or comprehensive insurance 
compared with high-deductible health plans, and insured 
status was associated with less consideration of costs in 
decision making.23
Twelve studies addressed the relationship between 
income and high costs. In three US studies, higher 
incomes were associated with high costs, whereas five 
Canadian studies found that lower incomes were asso-
ciated with (mental health) high costs. However, one 
US, one Taiwanese and one Canadian study reported 
that income was not significantly related to high costs. 
Finally, among high-cost US Medicare patients, personal 
resources and education were associated with increased 
use of resources (higher socioeconomic status (SES) 
was linked to higher priced care) and also with lower 
resources use.23
Organisational enabling factors
The number of primary care physicians, specialists 
and hospital beds were associated with higher per 
capita preventable costs among high-cost US Medicare 
patients.26 Reschovsky et al27 found several weak or insig-
nificant relationships between organisational factors and 
high costs within the high-cost population but found 
that high-cost US Medicare patients more likely had a 
medical specialist as usual source of care than a primary 
care physician or surgeon. Finally, high-cost US Medicare 
patients were only modestly concentrated in hospitals 
and markets (they were widely distributed through the 
system). High concentration hospitals (with relatively 
many high-cost patients) had a 15% higher median cost 
per claim, were more likely for-profit and teaching hospi-
tals, had lower nurse-to-patient ratios, were more likely 
to care for the poor and had higher 30-day readmission 
rates and lower 30-day mortality rates. High concentra-
tion hospital referral regions had higher annual median 
costs per beneficiary, a larger supply of specialists but 
equal supply of total physicians, a lower supply of long-
term care beds, higher hospital care intensity and higher 
end-of-life spending.28
need characteristics
Medical characteristics of high-cost patients are 
presented in table 2. We categorised medical character-
istics to ICD-10 chapters. Circulatory diseases, mental 
and behavioural disorders, endocrine, nutritional and 
metabolic, diseases of the respiratory system, diseases of 
the genitourinary system, neoplasms and diseases of the 
musculoskeletal system and connective tissue were most 
frequently reported among high-cost patients. The preva-
lence of chronic disease(s) and multimorbidity were also 
dominant among high-cost patients. For example, Bynum 
et al16 showed that over 26.4% of high-cost US dual eligi-
bles suffered from five or more chronic conditions.
Two studies presented medical characteristics across 
US payers. Both studies showed that high-cost commer-
cial patients had the lowest numbers of comorbidities and 
that high-cost Medicaid patients had the highest preva-
lence of mental illness.9 29 We further compared the prev-
alence of diabetes, congestive heart failure, lung disease 
and mental disorders across the studies. The prevalence 
of diabetes, congestive heart failure and lung disease was 
relatively low (≈5%–25%) in US commercial and total 
population studies. In US Medicaid, the prevalence of 
congestive heart failure and lung disease were relatively 
high (≈15%–40%; one study reported a prevalence of 
diabetes and lung disease >60%30), and the prevalence 
of mental illness was particularly high (≈30%–75%). In 
US Medicare, the prevalence of diabetes, congestive heart 
failure and lung disease were highest (≈20%–55%) and 
the prevalence of mental illness more modest (≈10%–
25%). In total populations, approximately 30%–40% 
of high-cost patients were treated for mental illness. 
Besides, the prevalence of each of the chronic diseases 
in the Dutch study was comparable with the prevalence 
in other total population studies. Finally, persistent high-
cost patients had a higher number of comorbidities and a 
higher prevalence of each of the diseases compared with 
episodic high-cost patients.
High-cost patients were more likely to die, and those in 
the process of dying were more likely to incur high costs. 
The mortality differed between payers, much less between 
countries. The mortality among Danish and Dutch high-
cost patients was comparable with the mortality in other 
total population studies. In US Medicare studies, the 
mortality ranged from 14.2% to 27.4%, compared with 
11.7% in one US Medicaid study and 5%–13% in total 
populations. In addition, top-1% patients were more 
likely to die compared with top-5% patients,17 31 and 
persistent high-cost patients were more likely to die than 
episodic high-cost patients.32 Finally, among US dual 
eligibles, mortality varied much across age and residence 
groups; nearly half of dual eligibles aged 65 years and 
older died.16
Expenditure patterns and healthcare utilisation
In each study, costs were heavily concentrated. The 
top-10% patients roughly accounted for about 68% of 
costs (range: 55%–77%), the top-5% patients accounted 
for about 55% of costs (range: 29%–65%) and top-1% 
patients for approximately 24% (range: 14%–33%) within 
a given year. Costs were generally less concentrated in US 
Medicare and more concentrated in total populations.
A wide range of parameters were used to describe high-
cost patients’ healthcare utilisation (table 3). Inpatient 
acute hospital care was most often reported as a primary 
expenditure category for high-cost patients. In line with 
this, 17 studies reported hospitalisations, admissions or 
inpatient days as important cost drivers. Lieberman found 
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that total spending per beneficiary correlated strongly 
with the use of inpatient services,33 likewise several studies 
found that increasing levels of use (ie, top-1% compared 
with top-5%) were associated with increasing proportions 
of spending on (inpatient) hospital care.15 17 23 24 34 35 Guo 
et al36 reported that high-cost users consumed more units 
of each of the service category analysed, with the excep-
tion of laboratory tests; these findings were confirmed 
elsewhere.35 37 In addition, it was found that 91% of 
high-cost patients received care in multiple care types.38 
Mental care services were listed as expenditure category 
only in studies of total populations, US Medicaid and US 
VA. Finally, one study determined the frequency use of 
expensive services among high-cost patients: expensive 
treatments (expensive drugs, intensive care unit treat-
ment, dialysis, transplant care, and Diagnosis Related 
Groups >€30 000) contributed to high cost in approxi-
mately one-third of top-1% patients and in less than 10% 
of top-2%–5% patients.17
Four studies quantified the amount of ‘preventable’ 
spending (based on preventable emergency department 
visits and preventable (re-)admissions) among high-cost 
patients. As shown above, various supply side characteris-
tics were associated with higher preventable costs among 
high-cost US Medicare patients, and approximately 10% 
of total costs were preventable.26 Another study found 
that 4.8% of US Medicare spending was preventable and 
that high-cost patients accounted for 73.8% of prevent-
able spending. Moreover, 43.8% of preventable spending 
was accounted for by frail elderly, and preventable 
spending was particularly high for heart failure, pneu-
monia, chronic obstructive pulmonary disease/asthma 
and urinary tract infections.39 Figueroa et al30 found that 
preventable spending differed by insurance type among 
US non-elderly: 3.5%, 2.8%, and 1.4% of spending were 
preventable among US Medicaid, US Medicaid managed 
care and privately insured high-cost patients, respectively. 
Similarly, Graven et al29 found that proportions of prevent-
able spending differed between payers and that persistent 
high-cost patients had higher proportions of preventable 
spending.
Twenty-one studies reported on the persistency of 
high costs. We found three approaches for studying 
persistency. First, studies reported prior healthcare use 
and/or reported posterior healthcare use for patients with 
high costs in a given index year. In other studies, persistent 
high-cost patients were compared with episodic high-cost 
patients. Spending persistency varied between 24% and 
48% for top-5% patients, and between 28% and 45% for 
top-10% patients. Spending persistence was relatively 
high in US Medicaid and relatively low in US Medicare. 
Increasing persistence was associated with increasing 
expenditures on all service types.37
DIsCussIOn
We reviewed 55 studies on high-cost patients’ character-
istics and healthcare utilisation and made comparisons 
across payers and countries. The studies consistently point 
to a high prevalence of multiple (chronic) conditions to 
explain high-cost patients’ utilisation. Besides, we found 
a high prevalence of mental illness across all the studies, 
most notably in US Medicaid and total population studies. 
We found that various health system characteristics may 
Table 3 Expenditure patterns and utilisation of high-cost patients
Spending category Number of studies
(Inpatient) hospital care 3115–19 22–25 27–30 32–39 60 66–68 73 75 78 79 82 85
Subacute care/postacute care services rehabilitation 119 15 22 27 30 35 38 39 66 67 75
Hospitalisations/admission/ patient days/length of stay 1717–19 23 26 35 36 39 60 68 73 74 77–79 81 85
Emergency department 1219 26 29 35–38 60 73 77 78 85
Outpatient (physician) visits 1319 27 34–37 39 65 73 77 82 83 85
Long-term care 1115 16 22 30 39 66 67 70 73 78 83
Mental health 1017 18 22 36 38 61 67 73 83 85
Physician services 1315 18 27 35–37 68 73 74 81–83 85
Intensive care unit 2 78 17
Prescription drugs 1617 19 23 30 35–37 62 65 67 68 75 77–79 85
Persistency
  Subsequent use 1316 20 21 23 29 31–33 62 67 72 82 83
  Prior use 521 32 58 60 65
  Persistent users 2115 16 20–23 26 29 31–33 37 57 58 60 62 65 67 72 82 83
Prediction of high-cost patients* 1622 25 58–60 63–65 68–70 77 79 80 83 84
*An in-depth discussion of prediction models for high costs is beyond the scope of the article (though individual predictors are used 
throughout the paper). Generally, diagnosis-based models outperform prior cost models, and combinations accurately predict high-cost 
patients. Besides, comorbidity indices also accurately predict high-cost patients, and self-reported health data meaningfully improved 
existing models.
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contribute to high costs. Preventable spending was esti-
mated at maximally 10% of spending. Furthermore, we 
found that high costs are associated with increasing age 
and that clinical diagnoses and utilisation patterns varied 
across age groups. However, still more than half of high-
cost patients are younger than 65 years. High costs were 
associated with higher incomes in the USA, but with lower 
incomes elsewhere. Finally, we confirmed that high-cost 
patients are more likely to die, and decedents are more 
likely to incur high-costs. However, no more than 30% of 
high-cost patients were in their last year of life.
strengths and weaknesses
This is the first systematic review of scientific literature 
on high-cost patients’ characteristics and healthcare util-
isation. Future studies might consider inclusion of grey 
literature. We included studies of various payer types 
and countries, allowing comparisons across settings. 
However, most studies were conducted in the USA and 
Canada, which limits the generalisability of the findings. 
Although our comparison across countries did not reveal 
large differences in mortality or prevalence of common 
chronic diseases, these analyses were based on a limited 
number of variables, studies and countries. It is likely that 
the specific characteristics and utilisation of high-cost 
patients vary across localisations due to a wide range of 
epidemiological and health system factors. One limita-
tion is that we, because of methodological diversity, did 
not assess the quality of the included studies, and some 
studies by design did not control for confounding. To 
our knowledge, no agreed on framework exists for risk 
of bias assessment of the kind of studies included in our 
review. One limitation in current frameworks for obser-
vation/cross-sectional studies is that these are primarily 
designed for studies that aim to assess intervention effects 
in comparative studies. The internal validity of the find-
ings in our included studies is mainly contingent on its 
ability to control for relevant confounders. However, no 
consensus exists about what factors should reasonably 
be controlled for. The external validity of the findings of 
each of the studies depend on the breadth of the popu-
lation studied and the scope of the costs considered for 
establishing total costs. Our study selection process was 
aimed at identifying studies with a broad population 
studies and a wide range of costs considered. Finally, the 
studies used various approaches for defining the needs 
and measuring multimorbidity among their populations, 
which limits the comparability across studies.
reflections on our findings
Current research in high-cost patients has focused on 
care redesign of the treatment of patients with multiple 
chronic morbidities.7 40 One contribution of our review 
is our identification of notable differences in characteris-
tics and utilisation across payers and countries. This (clin-
ical) diversity of high-cost patients may even be larger at 
a local level. Segmentation analysis has been suggested 
as a method to identify homogenous and meaningful 
segments of patients with similar characteristics, needs 
and behaviour, which allows for tailored policy.41 Such 
segmentation analysis may powerfully inform popula-
tion health management initiatives. Given the multiple 
needs and cross-sectoral utilisation of high-cost patients, 
we suggest such analyses should capture both character-
istics and utilisation as broadly as possible, to fully appre-
hend high-cost patients care needs and utilisation. In 
the context of high-cost patients, multimorbidity compli-
cates segmentation, and the usefulness of segmentation 
may depend on the way multimorbidity is dealt with. To 
illustrate a potent example, Hayes et al42 defined high-
need, high-cost patients as ‘people having three or more 
chronic conditions and a functional limitation that makes 
it hard for them to perform basic daily tasks’.
Our findings also reveal several supply-side factors 
that contribute to high costs. However, no firm conclu-
sions can be drawn about the strength of these effects. 
The apparent limited impact of organisational factors on 
spending is in line with Andersen’s model predictions, 
where multimorbidity and health status are prime deter-
minants of healthcare costs.43 However, such findings are 
surprising given the abundance of evidence for supplier 
induced demand and medical practice variation.44 High-
cost populations may be too diverse for studying the 
impact of organisational factors; for such studies, more 
homogenous populations may be prerequisite.
Four of our included studies estimated the amount 
of ‘preventable’ spending among high-cost patients. 
Preventable spending was estimated at maximally 10% 
of spending, which is relatively low compared with the 
amounts of savings that have been reported elsewhere.8 
Preventable spending was mainly defined as prevent-
able emergency department visits or preventable (re-)
admissions, as such echoing the two primary targets of 
most high-need high-cost programmes, including care 
coordination and disease management. The algorithms 
used were said to be relatively narrow and could have 
included other diagnostic categories.29 Besides, future 
studies might consider more broad measures of prevent-
able or wasteful spending and develop algorithms to iden-
tify duplicate services, contraindicated care, unnecessary 
laboratory testing, unnecessary prolonged hospitalisa-
tions or any other kinds of lower value services.
It was striking that three US studies reported that 
higher incomes were associated with high costs, whereas 
other studies found that lower incomes were associated 
with high costs. These findings may point to disparities 
in health, the price that some Americans pay for their 
care and the reduced accessibility to care of low-income 
patients. This may particularly hold for the uninsured. 
Besides, these findings suggest tailored interventions for 
lower income patients may be worthwhile.
Policy and research implications
Based on our findings, we deduced four major segments 
of high-cost patients for which separate policy may be 
warranted, including patients in their last year of life, 
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patients experiencing a significant health event who 
return to stable health (episodically high-cost patients), 
patients with mental illness and patients with persistently 
high costs characterised by chronic conditions, functional 
limitations and elder age.
Many interventions have been taken to increase value 
of end-of-life care. Advance care planning has shown 
to increase the quality of end-of-life care and decrease 
costs.45–47 In addition, health systems might consider 
strengthening their palliative care systems.48 Increasing 
value for episodically high-cost patients requires appro-
priate pricing of procedures and drugs, for example, 
through selective contracting of providers, reference 
pricing or competitive bidding.49 In addition, bundled 
payments for procedures and associated care may improve 
care coordination and reduce the use of duplicative or 
unnecessary services.50 Multidisciplinary needs assess-
ment and shared decision making may reduce unwar-
ranted variation in expensive procedures. Mental health 
high-cost patients are known for their medical comor-
bidities, which suggests these patients might benefit 
from multidisciplinary cross-sectoral healthcare delivery, 
for example, through collaborative care.51 52 Finally, 
persistent high-cost patients might benefit from a variety 
of models, including disease management, care coordina-
tion or ambulatory intensive care units, depending on the 
needs of the population and local circumstances.8 53–55 
Especially population health management approaches 
may be beneficial for these populations. Sherry et al 
recently examined five community-oriented programmes 
that successfully improved care for high-need, high-cost 
patients. The five programmes shared common attri-
butes, including a ‘whole person’ orientation, shared 
leadership, flexible financing and shared cross-system 
governance structures.56
One study addressed health beliefs and patient networks 
among high-cost patients.23 More of such research is 
needed as health beliefs may be more amenable to change 
than other drivers of high costs. One study analysed the 
use of expensive treatments by high-cost patients.17 Better 
insight in such healthcare utilisation patterns is needed to 
inform interventions and policy aimed at high-cost popu-
lations. There is a need for segmentation variables and 
logic that is informative at either microlevel, mesolevel 
and macrolevel. More research is needed to identify 
determinants of preventable and wasteful spending.
In conclusion, high-cost patients make up the sickest 
and most complex populations, and their high utilisa-
tion is primarily explained by high levels of chronic and 
mental illness. High-cost patients are diverse popula-
tions and vary across payer types and countries. Tailored 
interventions are needed to meet the needs of high-cost 
patients and to avoid waste of scarce resources.
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